Incyte Genomics Inc (INCY)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Incyte Genomics Inc (INCY)
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Key Insights
Critical company metrics and information
Share Price
$73.66Market Cap
$14.19 BillionTotal Outstanding Shares
192.65 Million SharesTotal Employees
2,524Dividend
No dividendIPO Date
November 3, 1993SIC Description
Services-commercial Physical & Biological ResearchHomepage
https://www.incyte.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Exchange Gains/Losses | $-7.84 Million |
Net Cash Flow From Financing Activities | $-2.04 Billion |
Net Cash Flow | $-1.92 Billion |
Net Cash Flow, Continuing | $-1.92 Billion |
Net Cash Flow From Operating Activities, Continuing | $101.85 Million |
Net Cash Flow From Investing Activities, Continuing | $24.48 Million |
Net Cash Flow From Financing Activities, Continuing | $-2.04 Billion |
Net Cash Flow From Operating Activities | $101.85 Million |
Net Cash Flow From Investing Activities | $24.48 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Revenues | $4.08 Billion |
Diluted Earnings Per Share | $0.14 |
Income/Loss From Continuing Operations Before Tax | $273.86 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Gross Profit | $3.78 Billion |
Basic Average Shares | $211.96 Million |
Research and Development | $2.59 Billion |
Income/Loss From Continuing Operations After Tax | $32.48 Million |
Other Operating Expenses | $40.78 Million |
Net Income/Loss Attributable To Parent | $32.48 Million |
Costs And Expenses | $4.13 Billion |
Benefits Costs and Expenses | $3.80 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Operating Expenses | $3.84 Billion |
Income Tax Expense/Benefit | $241.38 Million |
Diluted Average Shares | $211.94 Million |
Operating Income/Loss | $-52.88 Million |
Basic Earnings Per Share | $0.17 |
Selling, General, and Administrative Expenses | $1.21 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Cost Of Revenue | $293.33 Million |
Net Income/Loss | $32.48 Million |
Net Income/Loss Available To Common Stockholders, Basic | $32.48 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Assets | $5.01 Billion |
Equity Attributable To Parent | $3.17 Billion |
Current Liabilities | $1.50 Billion |
Equity | $3.17 Billion |
Noncurrent Liabilities | $339.56 Million |
Liabilities And Equity | $5.01 Billion |
Inventory | $70.44 Million |
Other Current Assets | $2.74 Billion |
Liabilities | $1.84 Billion |
Accounts Payable | $178.71 Million |
Wages | $150.72 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Fixed Assets | $773.10 Million |
Noncurrent Assets | $2.20 Billion |
Other Current Liabilities | $1.17 Billion |
Other Non-current Assets | $1.43 Billion |
Current Assets | $2.81 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.